• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
Grand Rounds

Can Smartwatches Play a Role in A-Fib Management?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Wearable devices and smartwatches (wearables), such as the Apple Watch and AliveCor Kardia Band (both cleared by the FDA), allow individuals with atrial fibrillation (AF) to monitor their heart rate and detect arrhythmias using single lead ECG technology       
  • Wang et al. (JAMA Network Open, 2021) characterized patients with AF who use wearables to determine health care use

METHODS:

  • Retrospective, cohort study
  • Participants
    • ≥1 AF-specific ICD-10 code from 2017 through 2019
  • Exposure
    • Use of commercially available wearables with pulse rate or rhythm evaluation capabilities
  • Study design
    • Electronic medical records were used to identify individuals who used wearables and had adequate pulse-rate follow-up
    • These individuals were propensity-matched (4 to 1) to individuals who did not use wearables
  • Primary outcome
    • Mean pulse rates
    • Composite health care use score: Evaluation and management | Ablation | Cardioversion | Telephone encounters | Number of rate or rhythm control medication orders

RESULTS:

  • 348 wearables users | 15,972 non-users
    • Apple most common, followed by Fitbit and Kardia
  • Wearables users were younger (P<0.001)
    • Mean (SD) age users: 64.0 (13.0) years vs non-users 70.0 (13.8) years
  • Users were also healthier (P<0.001)
    • Mean (SD) CHA2DS2-VASc score: 3.6 (2.0) vs 4.4 (2.0)
  • There was no gender bias (P=0.91)
    • 42.5% women vs 42.1% women
  • After matching, mean pulse rate was similar between 125 patients using wearables vs 500 patients not using wearables (P=0.04)
    • Users: 75.01 (95% CI, 72.74 to 77.27) bpm
    • Non-users: 75.79 (95% CI, 74.68 to 76.90) bpm
  • There was a significant difference in use of ablation, occurring in more individuals who used wearables (P=0.001)
    • Users: 17.6%
    • Non-Users: 7.4%
  • Mean composite use score was 0.28 points (95% CI, 0.01 to 0.56) higher among individuals using wearables
  • Mean pulse was similar between the groups
    • Difference −0.79 bpm (95% CI, −3.28 to 1.71)

CONCLUSION:

  • Individuals with AF who use wearable devices or smartwatches had more follow-up health care use than non-users with similar pulse rates
  • The authors state

This study’s finding suggests that wearable use among patients with AF is associated with increased health care use and support the need for randomized clinical trials to measure the impact of wearables on health outcomes and use among patients with AF

Learn More – Primary Sources:

Association of Wearable Device Use With Pulse Rate and Health Care Use in Adults With Atrial Fibrillation

Want to stay on top of key guidelines and research papers?

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite
< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

RCT Results: Does Early Rhythm Control Improve Outcomes for Patients with Atrial Fibrillation?
Rhythm Control for Atrial Fibrillation: Does Timing of Treatment Initiation Matter?
Do More Pregnancies Increase Risk of Atrial Fibrillation?

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Download Your ObG App
HERE!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site